The landscape of therapeutic drugs is undergoing a transformative phase, driven by significant strides in bioprocessing technologies and innovative biotechnological advancements. One of the most notable developments in recent years has been the shift towards personalized medicine, which tailors
When thinking about the remarkable advancements in multiple myeloma treatment, CAR T-cell therapy generates immense excitement due to its potential to provide deep and enduring responses for patients. Dr. Nina Shah, Global Head of Multiple Myeloma Clinical Development and Strategy at AstraZeneca,
Checkpoint inhibitor therapies have revolutionized cancer treatment by enhancing the immune system's ability to target and destroy cancer cells. By boosting the immune response, these therapies have made significant strides in prolonging the lives of patients with various types of cancer.
Multiple myeloma (MM), a complex form of blood cancer originating in plasma cells, relentlessly impairs blood counts and immune functions. Despite breakthroughs in treatment modalities, MM largely remains incurable, with patients often enduring cycles of remission interrupted by relapses. This
The fight against advanced melanoma, a particularly aggressive form of skin cancer, has long been hindered by the cancer's ability to develop resistance to conventional treatments. However, a groundbreaking study led by QUT researchers at Brisbane's Translational Research Institute (TRI)
Lambert-Eaton myasthenic syndrome (LEMS) is a rare and debilitating autoimmune disorder where the immune system mistakenly attacks the body's own tissues, specifically targeting voltage-gated calcium channels (VGCCs) on nerve cells. This disruption in nerve-muscle communication results in
